Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A

Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A

Potency is a key optimization parameter for hemophilia A gene therapy product candidates. Optimization strategies include promoter engineering to increase transcription, codon optimization of mRNA to improve translation, and amino-acid substitution to promote secretion. Herein, we describe both rati...

Full description

Bibliographic Details
Main Authors:	Harrison C. Brown, Philip M. Zakas, Stephan N. George, Ernest T. Parker, H. Trent Spencer, Christopher B. Doering
Format:	Article
Language:	English
Published:	Elsevier 2018-06-01
Series:	Molecular Therapy: Methods & Clinical Development
Online Access:	http://www.sciencedirect.com/science/article/pii/S2329050118300056

Similar Items

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
by: Harrison C Brown, et al.
Published: (2014-01-01)

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII
by: Athena L. Russell, et al.
Published: (2021-06-01)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
by: Allison M Lytle, et al.
Published: (2016-01-01)

Platelet-Targeted Gene Therapy for Hemophilia
by: Qizhen Shi
Published: (2018-06-01)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
by: Nadia El-Akabawy, et al.
Published: (2020-06-01)

Development and characterization of recombinant ovine coagulation factor VIII.
by: Philip M Zakas, et al.
Published: (2012-01-01)

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A
by: Christopher Stem, et al.
Published: (2021-08-01)

Status and Prospect of Gene Therapy for Hemophilia
by: DAI Xinyue, et al.
Published: (2022-10-01)

Gene Therapy in Hemophilia: Recent Advances
by: E. Carlos Rodríguez-Merchán, et al.
Published: (2021-07-01)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
by: Seema R. Patel, et al.
Published: (2020-04-01)

Direct-to-consumer Marketing to People with Hemophilia.
by: Philip Kucab, et al.
Published: (2016-06-01)

Gene Therapy in Hemophilia: From Hype to Hope
by: Roger Schutgens
Published: (2018-04-01)

Gene Therapy Approaches for the Treatment of Hemophilia B
by: Anastasiia B. Soroka, et al.
Published: (2023-06-01)

The Arrival of Gene Therapy for Patients with Hemophilia A
by: Giancarlo Castaman, et al.
Published: (2022-09-01)

Gene therapy for hemophilia, a clinical viewpoint
by: Sheng-Chieh Chou, et al.
Published: (2023-11-01)

The intersection of vector biology, gene therapy, and hemophilia
by: Leszek Lisowski, et al.
Published: (2021-08-01)

Bioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy
by: Xiaoli Yu, et al.
Published: (2020-05-01)

Nonfactor Therapies for Hemophilia
by: Guy Young
Published: (2023-06-01)

Gene Therapy for Hemophilia A: How Long Will It Last?
by: Roger E. G. Schutgens
Published: (2022-06-01)

Hemophilia Gene Therapy: Approaching the First Licensed Product
by: Paul Batty, et al.
Published: (2021-03-01)

Big stride in gene therapy for hemophilia B in China
by: Jianmin Wang, et al.
Published: (2023-04-01)

Gene Therapy in Hemophilia: A Transformational Patient Experience
by: Enayet Rasul, et al.
Published: (2023-08-01)

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
by: Benjamin J. Samelson-Jones, et al.
Published: (2019-03-01)

Editorial: Bioengineered gene and cell therapy for treating cardiovascular diseases
by: Kai Wang, et al.
Published: (2023-08-01)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
by: Yuanhua Cai, et al.
Published: (2020-06-01)

Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
by: Jan Astermark, et al.
Published: (2023-10-01)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
by: Midori Shima
Published: (2020-05-01)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
by: Flora Peyvandi, et al.
Published: (2020-05-01)

Editorial: Modern Approaches to Hemophilia Management: Gene Therapy and Beyond
by: Daniel Coriu, et al.
Published: (2022-04-01)

Developments in the treatment of hemophilia B: focus on emerging gene therapy
by: Cancio MI, et al.
Published: (2013-10-01)

Bioengineering coagulation factors for improved hemophilia treatments : Comment on: the mutation F309S increases FVIII secretion in human cell line
by: Bidossessi Wilfried Hounkpe, et al.

Emerging and future therapies for hemophilia
by: Carr ME, et al.
Published: (2015-09-01)

Bioengineered Ferritin Nanocarriers for Cancer Therapy
by: Xuanrong Sun, et al.
Published: (2021-06-01)

Editorial: Bioengineered Nanoparticles in Cancer Therapy
by: Payam Zarrintaj, et al.
Published: (2021-07-01)

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
by: Benjamin J. Samelson-Jones, et al.
Published: (2020-04-01)

Methods in bioengineering : nanoscale bioengineering and nanomedicine /
by: Rege, Kaushal, et al.
Published: (2009)

Methods in bioengineering : stem cell bioengineering /
by: Parekkadan, Biju, et al.
Published: (2009)

Gene Therapy and Hemophilia: Where Do We Go from Here?
by: Bolous NS, et al.
Published: (2022-10-01)

The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients
by: Miesbach W, et al.
Published: (2020-04-01)

Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders
by: Odiba Arome Solomon, et al.
Published: (2021-05-01)